BerGenBio ASA (BRRGF)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BRRGF steht fuer BerGenBio ASA, ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Die Aktie erreicht einen hohen Ueberzeugungsscore von 74/100 ueber fundamentale, technische und Stimmungsfaktoren.
Zuletzt analysiert: 17. März 2026BerGenBio ASA (BRRGF) Gesundheitswesen & Pipeline-Uebersicht
BerGenBio ASA, a Norwegian clinical-stage biopharmaceutical company, specializes in developing AXL inhibitor therapies like Bemcentinib for cancers and respiratory diseases. With a focus on immune evasion and drug resistance, BerGenBio navigates the competitive biotech landscape through strategic collaborations and Phase II clinical trials, targeting unmet medical needs.
Investmentthese
BerGenBio ASA presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's lead drug candidate, Bemcentinib, targeting the AXL receptor, is in Phase II clinical trials for multiple cancer indications and COVID-19, representing a significant potential value driver. Positive clinical trial results could lead to substantial stock appreciation. The collaboration with Merck & Co. provides validation and potential for future partnerships. However, the company's negative profit margin of -1990.4% and reliance on clinical trial success pose substantial risks. The company's small size and limited resources also present operational challenges. Investors should closely monitor clinical trial data and partnership developments to assess the company's progress and potential for long-term growth.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market Cap of $9.49 billion, reflecting investor expectations for future growth and potential success of its clinical trials.
- Gross Margin of 98.1%, indicating strong potential profitability if clinical trials are successful and products are commercialized.
- P/E Ratio of -16.51, reflecting the company's current lack of profitability due to its clinical-stage status.
- Beta of 1.31, indicating higher volatility compared to the overall market, typical for biotechnology companies with ongoing clinical trials.
- Lead candidate Bemcentinib in Phase II clinical development across multiple cancer indications, representing a key value driver.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary AXL inhibitor technology.
- Lead candidate Bemcentinib in Phase II clinical trials.
- Collaboration agreement with Merck & Co.
- Focus on addressing unmet medical needs in oncology and respiratory diseases.
Schwaechen
- Clinical-stage company with no currently approved products.
- Negative profit margin and reliance on external funding.
- Small size and limited resources.
- High dependence on clinical trial outcomes.
Katalysatoren
- Ongoing: Phase II clinical trial results for Bemcentinib in non-small cell lung cancer.
- Ongoing: Phase II clinical trial results for Bemcentinib in acute myeloid leukemia.
- Ongoing: Phase II clinical trial results for Bemcentinib in myelodysplastic syndrome.
- Upcoming: Potential announcement of new strategic partnerships or licensing agreements.
- Upcoming: Publication of scientific data related to AXL inhibition and BerGenBio's drug candidates.
Risiken
- Potential: Clinical trial failures for Bemcentinib or tilvestamab.
- Potential: Regulatory hurdles and delays in obtaining drug approvals.
- Ongoing: Competition from other biopharmaceutical companies developing similar therapies.
- Ongoing: Dependence on external funding and potential dilution of existing shareholders.
- Potential: Patent expiration and generic competition for BerGenBio's drug candidates.
Wachstumschancen
- Expansion of Bemcentinib into New Cancer Indications: Bemcentinib, BerGenBio's lead candidate, holds potential for expansion into additional cancer indications beyond its current Phase II trials. The global cancer therapeutics market is projected to reach $286 billion by 2028. Positive clinical trial results in new cancer types could significantly increase Bemcentinib's market potential. This expansion strategy could be pursued within the next 2-3 years, contingent on ongoing trial outcomes.
- Advancement of Tilvestamab to Later-Stage Clinical Trials: Tilvestamab, BerGenBio's anti-AXL antibody, is currently in Phase Ib clinical trials. Successful completion of Phase Ib and progression to Phase II trials would represent a significant milestone. The antibody therapeutics market is expected to grow, driven by the increasing demand for targeted therapies. Advancement of Tilvestamab could occur within the next 3-5 years, depending on trial results and funding.
- Strategic Partnerships and Licensing Agreements: BerGenBio can pursue strategic partnerships and licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. The pharmaceutical industry is characterized by collaborations and partnerships to share risks and resources. Securing such agreements could provide BerGenBio with funding and expertise to advance its pipeline. These partnerships could materialize within the next 1-2 years.
- Expansion into Respiratory Disease Therapies: BerGenBio's research and development efforts in respiratory diseases, including COVID-19, represent a growth opportunity. The respiratory disease therapeutics market is substantial, driven by the prevalence of conditions like asthma, COPD, and infectious respiratory illnesses. Success in developing effective therapies for these diseases could generate significant revenue. This expansion could yield results in the next 2-4 years, depending on clinical trial progress.
- Exploration of AXL Inhibitor Combinations: BerGenBio can explore the potential of combining its AXL inhibitors with other cancer therapies, such as chemotherapy or immunotherapy. Combination therapies are increasingly common in oncology, aiming to improve treatment efficacy and overcome drug resistance. Positive results from combination studies could lead to new treatment regimens and market opportunities. This exploration could begin within the next 1-2 years, with clinical trial data emerging over the subsequent years.
Chancen
- Expansion of Bemcentinib into new cancer indications.
- Advancement of tilvestamab to later-stage clinical trials.
- Strategic partnerships and licensing agreements.
- Expansion into respiratory disease therapies.
Risiken
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from other biopharmaceutical companies.
- Patent expiration and generic competition.
Wettbewerbsvorteile
- Proprietary AXL inhibitor technology: BerGenBio has developed a portfolio of AXL inhibitors, including Bemcentinib and tilvestamab, which are protected by patents.
- Clinical trial expertise: The company has experience in conducting clinical trials, which is essential for drug development.
- Collaboration with Merck & Co.: The collaboration with Merck & Co. provides validation and access to resources.
- Focus on a specific target: BerGenBio's focus on AXL inhibition allows it to develop specialized expertise and potentially achieve superior efficacy compared to broader-spectrum therapies.
Ueber BRRGF
BerGenBio ASA, founded in 2007 and based in Bergen, Norway, is a clinical-stage biopharmaceutical company dedicated to developing innovative drugs for the treatment of cancer and respiratory diseases. The company's primary focus is on addressing immune evasive, drug resistant, and metastatic cancers. BerGenBio's lead candidate, Bemcentinib, is a bio-available small molecule AXL inhibitor currently undergoing Phase II clinical development across various cancer indications and COVID-19. Bemcentinib aims to improve patient outcomes by targeting the AXL receptor tyrosine kinase, a key driver of tumor growth, survival, and drug resistance. The company's Phase II clinical trial program encompasses non-small cell lung cancer, acute myeloid leukemia, and myelodysplastic syndrome, as well as COVID-19. In addition to Bemcentinib, BerGenBio is also developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. This antibody is designed to block AXL signaling and enhance the anti-tumor immune response. BerGenBio has established a collaboration agreement with Merck & Co. for clinical trials, enhancing its research and development efforts. With a lean team of 13 employees, BerGenBio is focused on advancing its pipeline of novel therapies to address significant unmet medical needs in oncology and respiratory diseases.
Was das Unternehmen tut
- Develop drugs to treat immune evasive cancers.
- Develop drugs to treat drug resistant cancers.
- Develop drugs to treat metastatic cancers.
- Develop drugs to treat respiratory diseases.
- Focus on AXL (AXL receptor tyrosine kinase) inhibition as a therapeutic strategy.
- Conduct Phase II clinical trials for Bemcentinib in various cancer indications.
- Develop anti-AXL antibodies like tilvestamab.
Geschaeftsmodell
- Develops proprietary drug candidates targeting AXL inhibition.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approval for its drug candidates from agencies like the FDA and EMA.
- Potentially commercializes its drugs directly or through partnerships with larger pharmaceutical companies.
Branchenkontext
BerGenBio ASA operates within the competitive biotechnology industry, characterized by high R&D costs, lengthy regulatory approval processes, and significant clinical trial risks. The industry is driven by innovation and the development of novel therapies for unmet medical needs. The global biotechnology market is projected to reach $3.87 trillion by 2030, growing at a CAGR of 12.3% from 2022. BerGenBio competes with other biopharmaceutical companies, including DOGP, FTHWF, GHSI, IPCIF, and IVITF, all vying for market share in oncology and respiratory disease therapeutics. Success in this industry hinges on clinical trial outcomes, regulatory approvals, and strategic partnerships.
Wichtige Kunden
- Patients with cancer (non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome).
- Patients with respiratory diseases (COVID-19).
- Healthcare providers who prescribe and administer BerGenBio's drugs.
- Pharmaceutical companies that may partner with BerGenBio for development and commercialization.
Finanzdaten
Chart & Info
BerGenBio ASA (BRRGF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer BRRGF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer BRRGF.
Kursziele
Wall-Street-Kurszielanalyse fuer BRRGF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von BRRGF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Oystein Soug
CEO
Oystein Soug serves as the CEO of BerGenBio ASA. Information regarding his detailed career history, education, and previous roles is not available in the provided data. His credentials and specific expertise remain unknown based on the current context.
Erfolgsbilanz: Oystein Soug currently manages 13 employees at BerGenBio ASA. Specific achievements, strategic decisions, and company milestones under his leadership are not detailed in the provided data. Therefore, a comprehensive assessment of his track record is not possible.
BRRGF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that BerGenBio ASA may not meet the minimum financial or reporting standards required for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited financial disclosure and may be subject to greater risks due to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, companies in bankruptcy, or those unwilling or unable to meet higher reporting standards.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure due to OTC Other tier status.
- Potential for price manipulation due to low trading volume.
- Higher risk of fraud or mismanagement compared to companies on major exchanges.
- Limited regulatory oversight and investor protection.
- Difficulty in obtaining accurate and timely information about the company.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Determine the company's cash flow and financial stability.
- Understand the company's capital structure and potential dilution.
- Consult with a qualified financial advisor before investing.
- Clinical-stage biopharmaceutical company with ongoing clinical trials.
- Collaboration agreement with Merck & Co.
- Focus on developing innovative therapies for unmet medical needs.
- Presence of a CEO and a team of employees.
- Incorporated in 2007, suggesting a history of operations.
Was Anleger ueber BerGenBio ASA (BRRGF) wissen wollen
What are the key factors to evaluate for BRRGF?
BerGenBio ASA (BRRGF) currently holds an AI score of 74/100, indicating high score. Key strength: Proprietary AXL inhibitor technology.. Primary risk to monitor: Potential: Clinical trial failures for Bemcentinib or tilvestamab.. This is not financial advice.
How frequently does BRRGF data refresh on this page?
BRRGF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BRRGF's recent stock price performance?
Recent price movement in BerGenBio ASA (BRRGF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary AXL inhibitor technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BRRGF overvalued or undervalued right now?
Determining whether BerGenBio ASA (BRRGF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BRRGF?
Before investing in BerGenBio ASA (BRRGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BRRGF to a portfolio?
Potential reasons to consider BerGenBio ASA (BRRGF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary AXL inhibitor technology.. Additionally: Lead candidate Bemcentinib in Phase II clinical trials.. The AI-driven MoonshotScore of 74/100 reflects strong quantitative fundamentals. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of BRRGF?
Yes, most major brokerages offer fractional shares of BerGenBio ASA (BRRGF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BRRGF's earnings and financial reports?
BerGenBio ASA (BRRGF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for BRRGF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on provided data and may not be exhaustive.
- AI analysis is pending and may provide further insights.